Autologous T cells are genetically engineered to express patient-specific T-cell receptors that recognize tumor neoantigen peptides presented by the patient's HLA. Binding of the neoantigen-HLA complex activates TCR signaling, driving T-cell activation, clonal expansion, cytokine release, and perforin/granzyme-mediated cytotoxicity, resulting in antigen-specific tumor cell killing.